Damora Therapeutics
DMRA
20.24
+0.69
+3.53%
Damora Therapeutics
US · DMRA
#3109 by market cap
Listed 1970
20.24
+0.69
+3.53%
Live - 5344 symbols - heartbeat 247s ago
· 2026-10-07 19:54
After-hours
20.24
0.00%
- Market cap
- 1.25B
- P/E (TTM)i
- -77.85
- P/Bi
- 3.24
- EPSi
- -3.98
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on DMRA?
Anonymous reader poll. Unscientific, not investment advice.
About Damora Therapeutics
Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf J?rgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsg?rd Schambye in 2011 and is headquartered in Waltham, MA.
- Founded
- 2011
- CEO
- Ms. Jennifer Ann Jarrett
- Employees
- 7
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- damoratx.com
Company profile
- Exchange
- US
- Symbol
- DMRA
- Market-cap rank
- #3109
- Listing date
- 1970-01-01
- Market cap
- 1.25B
- Float cap
- 827.55M
- Shares out
- 61.74M
- Float shares
- 40.89M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.